Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Re-Launch Approved With MRI Requirement

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.

You may also be interested in...



Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s

Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.

Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s

Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.

Biogen Idec/Elan Submit Tysabri sBLA For Crohn’s Disease

Submission includes labeling and risk management plan to address increased risk of progressive multifocal leukoencephalopathy.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel